Retrospective Collection of Safety and Performance Data
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Lisboa, Portugal
- Hospital Lusiadas Lisboa
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients treated with Bioceramed bone substitutes at the Center.
- Long bone & extremities: bone grafting after post-traumatic or surgically created bone defects.
- Spine: degenerative disc disease or trauma who require spinal fusion of 1 or more vertebral bodies.
Exclusion Criteria:
Serious infection within two months before surgery, active malignancy, cellulitis, osteomyelitis, diseases interfering with bone metabolism (primary hyperparathyroidism, severe renal or hepatic insufficiency, non-treated hyperthyroidism), other bone metabolic diseases (osteomalacia, Paget disease, osteogenesis imperfecta), bone metastasis, primary bone tumors.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Granules in long bone & extremities
Filling of post-traumatic or surgically created bone defects
|
Orthopaedic or Spine bony defects
|
|
Wedges in long bone & extremities
Osteotomies with fixation
|
Orthopaedic or Spine bony defects
|
|
HA paste in long bone & extremities
Filling of post-traumatic or surgically created bone defects
|
Orthopaedic or Spine bony defects
|
|
Granules in Spine
Spinal cage filling
|
Orthopaedic or Spine bony defects
|
|
HA paste in Spine
Spinal cage filling
|
Orthopaedic or Spine bony defects
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone healing, observable by x-ray/MRI
Time Frame: 6 months
|
Primary endpoint will be successful radiographic bone repair.
|
6 months
|
|
Bone healing, observable by x-ray/MRI
Time Frame: 12 months
|
Primary endpoint will be successful radiographic bone repair.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number and description of any adverse event during the follow-up
Time Frame: 6 - 12 months
|
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
|
6 - 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nuno A Ribeiro, MD, Hospital Lusiadas Lisboa
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2020.09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.